8-K: Achieve Life Sciences Secures $10 Million Convertible Debt Facility, With Potential for Additional $10 Million

Achieve Life Sciences has entered into a new contingent convertible debt agreement for $10 million, with an additional $10 million potentially available, to refinance its existing debt and support operations.

Summary

• Achieve Life Sciences has secured a $10 million contingent convertible debt agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company.
• The agreement includes an option for an additional $10 million in term loans, contingent on certain milestones.
• The initial $10 million loan was advanced on July 25, 2024, and refinances a previous $16.6 million debt agreement from May 15, 2023.
• A second tranche of $5 million is available if the FDA accepts Achieve's New Drug Application for cytisinicline by October 31, 2025.
• A third tranche of $5 million is available at the lender's discretion by December 31, 2025.
• The loan matures on December 1, 2027, with a possible extension to June 1, 2028.
• Interest is calculated at a floating rate, the greater of 7% or the prime rate minus 1%, payable monthly.
• The loan is interest-only until December 31, 2025, with a possible extension.
• The debt can be converted into common stock at $7.00 per share for the initial tranche, and at a variable price for the second and third tranches.
• The conversion price for the second and third tranches is the greater of $4.854 or 150% of the average or closing price of the stock prior to the tranche effective date.
• The maximum number of shares issuable upon conversion is 1,428,571 for the initial tranche and 2,060,156 for the subsequent tranches.
• Automatic conversion occurs if the stock price reaches $24.00 for the initial tranche or three times the applicable conversion price for the subsequent tranches for 30 consecutive trading days, and liquidity conditions are met.
• The lender is restricted from short selling or hedging Achieve's stock while the debt is outstanding.
• Achieve has also entered into a Registration Rights Agreement, requiring them to register the shares issuable upon conversion for resale within 30 days.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company has secured funding, but the terms include potential dilution and restrictions. The deal is fairly standard for a company of this type.

Positives

• The new debt facility provides Achieve with $10 million in immediate funding.
• There is potential for an additional $10 million in funding, contingent on milestones.
• The loan refinances existing debt, potentially improving the company's financial structure.
• The interest-only period until December 31, 2025, provides some financial flexibility.
• The conversion feature could be beneficial for the lender if the stock price increases significantly.
• The lender is restricted from short selling or hedging Achieve's stock, which may reduce downward pressure on the stock price.

Negatives

• The debt is secured by substantially all of Achieve's assets, excluding intellectual property.
• The loan has a floating interest rate, which could increase if the prime rate rises.
• The conversion feature could dilute existing shareholders if exercised.
• The second and third tranches are not guaranteed, depending on FDA acceptance and lender discretion.
• The company is restricted from paying dividends or making other distributions on its capital stock, subject to limited exceptions.
• The lender has the right to convert the debt into shares at any time prior to repayment, which could lead to dilution.

Risks

• The additional $10 million in funding is not guaranteed and depends on FDA approval and lender discretion.
• The floating interest rate could increase the cost of borrowing if the prime rate rises.
• Conversion of the debt into equity could dilute existing shareholders.
• The company is restricted from paying dividends or making other distributions on its capital stock.
• The lender has the right to convert the debt into shares at any time prior to repayment, which could lead to dilution.
• The company's obligations under the debt agreement are secured by substantially all of its assets, excluding intellectual property, which could be a risk in case of default.

Future Outlook

The document outlines the terms of the debt agreement and the conditions for additional funding, but does not provide specific forward-looking statements about the company's future performance or financial guidance. The company's ability to access the additional $10 million in funding is contingent on FDA approval and lender discretion.

Industry Context

This announcement is typical for a biotech company seeking funding to support its drug development programs. Convertible debt is a common financing tool in the biotech industry, allowing companies to access capital while providing lenders with potential upside through equity conversion. The terms of the agreement, including the interest rate and conversion prices, are reflective of the risk associated with early-stage biotech companies.

Comparison to Industry Standards

• The use of convertible debt is a common practice for biotech companies, especially those in the clinical stage like Achieve Life Sciences.
• The interest rate of 7% or prime minus 1% is within the typical range for such financings, reflecting the risk profile of the company.
• The conversion price of $7.00 for the initial tranche and the variable price for subsequent tranches are structured to incentivize the lender while providing a potential upside for the company.
• The automatic conversion feature based on stock price performance is also a common feature in convertible debt agreements.
• Compared to other similar deals, the terms are fairly standard, with the additional tranches contingent on specific milestones, which is a common risk mitigation strategy for lenders.
• Companies like Cassava Sciences and Amylyx Pharmaceuticals have also used convertible debt to fund their operations, with similar terms and conditions.

Stakeholder Impact

• Shareholders may experience dilution if the debt is converted into equity.
• Employees may benefit from the company's increased financial stability.
• Customers may benefit from the continued development of the company's products.
• Creditors are secured by substantially all of the company's assets, excluding intellectual property.
• Suppliers may benefit from the company's increased financial stability.

Next Steps

• Achieve Life Sciences will need to seek FDA acceptance of its New Drug Application for cytisinicline to trigger the second tranche of the loan.
• The company will need to manage its cash flow to meet the interest payments and potential principal repayments.
• Achieve will need to register the shares issuable upon conversion for resale within 30 days.
• The company will need to monitor its stock price to avoid automatic conversion of the debt.

Key Dates

Keywords

convertible debt, term loan, refinancing, cytisinicline, FDA, drug application, stock conversion, Silicon Valley Bank, First-Citizens Bank, registration rights